Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
- DOI
- 10.1136/jitc-2025-013222
- Published
- 2025 Dec 23
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2025-013222,
title = {Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.},
author = {Porter R and Bockorny B and Corr BR and Mahadevan D and Wilky BA and El-Khoueiry AB and Bullock AJ and Hafez N and Moser J and Martynova A and Stebbing J and Joshi B and Bourdelais S and Delepine C and Chand D and Wu W and Johnson B and Grossman JE and O'Day SJ and Matulonis UA and Gordon MS},
year = {2025},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2025-013222},
url = {https://doi.org/10.1136/jitc-2025-013222}
}RIS
TY - JOUR TI - Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. AU - Porter R AU - Bockorny B AU - Corr BR AU - Mahadevan D AU - Wilky BA AU - El-Khoueiry AB AU - Bullock AJ AU - Hafez N AU - Moser J AU - Martynova A AU - Stebbing J AU - Joshi B AU - Bourdelais S AU - Delepine C AU - Chand D AU - Wu W AU - Johnson B AU - Grossman JE AU - O'Day SJ AU - Matulonis UA AU - Gordon MS PY - 2025 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2025-013222 UR - https://doi.org/10.1136/jitc-2025-013222 ER -
APA
R, P., B, B., BR, C., D, M., BA, W., AB, E., AJ, B., N, H., J, M., A, M., J, S., B, J., S, B., C, D., D, C., W, W., B, J., JE, G., SJ, O., UA, M., & MS, G. (2025). Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-013222